Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAM-001 in Sarcoidosis Associated Pulmonary Hypertension (SAPH)
NCT07886554Phase 2Not yet recruiting
- Sponsor
- IRulya Therapeutics
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in Sarcoidosis-associated pulmonary hypertension (SAPH), sponsored by IRulya Therapeutics. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
Sarcoidosis-associated pulmonary hypertension (SAPH)
Beyond the preview
Go deeper on NCT07886554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07886554.